Can a targeted pill finish off hidden CLL cells?
NCT ID NCT02649387
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 26 times
Summary
This study tested the drug ibrutinib in 35 people with chronic lymphocytic leukemia (CLL) who still had small amounts of cancer after their first treatment. The goal was to see if ibrutinib could clear those leftover cells from the blood and bone marrow. Participants took ibrutinib pills, and doctors checked for signs of cancer over time. The study looked at side effects and how long the cancer stayed away.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE I CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224-9980, United States
Conditions
Explore the condition pages connected to this study.